SLC5A2 and diabetic ketoacidosis: In addition, while no cases of euglycemic diabetic ketoacidosis (euDKA) were observed in this study, the potential for euDKA—particularly in insulin-treated patients—has been described in human medicine and should be considered when using SGLT2 inhibitors clinically [19].